Identification of two novel anti-fibrotic benzopyran compounds produced by engineered strains derived from Streptomyces xiamenensis M1-94P that originated from deep-sea sediments

The benzopyran compound obtained by cultivating a mangrove-derived strain, Streptomyces xiamenensis strain 318, shows multiple biological effects, including anti-fibrotic and anti-hypertrophic scar properties. To increase the diversity in the structures of the available benzopyrans, by means of bios...

Full description

Saved in:
Bibliographic Details
Published in:Marine drugs 2013-10, Vol.11 (10), p.4035-4049
Main Authors: You, Zhong-Yuan, Wang, Ya-Hui, Zhang, Zhi-Gang, Xu, Min-Juan, Xie, Shu-Jie, Han, Tie-Sheng, Feng, Lei, Li, Xue-Gong, Xu, Jun
Format: Article
Language:English
Subjects:
anti-fibrosis
benzopyran
Benzopyrans - chemistry
Benzopyrans - pharmacology
Fibroblasts - drug effects
Fibrosis - drug therapy
Geologic Sediments - chemistry
Geologic Sediments - microbiology
Humans
Lung - drug effects
Mutation - genetics
ribosome engineering
Ribosomes - genetics
Streptomyces - chemistry
Streptomyces - genetics
Streptomyces xiamenensis
Threonine - analogs & derivatives
Threonine - chemistry
Threonine - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The benzopyran compound obtained by cultivating a mangrove-derived strain, Streptomyces xiamenensis strain 318, shows multiple biological effects, including anti-fibrotic and anti-hypertrophic scar properties. To increase the diversity in the structures of the available benzopyrans, by means of biosynthesis, the strain was screened for spontaneous rifampicin resistance (Rif), and a mutated rpsL gene to confer streptomycin resistance (Str), was introduced into the S. xiamenensis strain M1-94P that originated from deep-sea sediments. Two new benzopyran derivatives, named xiamenmycin C (1) and D (2), were isolated from the crude extracts of a selected Str-Rif double mutant (M6) of M1-94P. The structures of 1 and 2 were identified by analyzing extensive spectroscopic data. Compounds 1 and 2 both inhibit the proliferation of human lung fibroblasts (WI26), and 1 exhibits better anti-fibrotic activity than xiamenmycin. Our study presents the novel bioactive compounds isolated from S. xiamenensis mutant strain M6 constructed by ribosome engineering, which could be a useful approach in the discovery of new anti-fibrotic compounds.
ISSN:1660-3397
1660-3397
DOI:10.3390/md11104035